Stock listing
Tradegate:CBHD Coloplast A/S Aktie
German listing (Tradegate) of Coloplast A/S · home listing Copenhagen:COLOB
Follow Coloplast A/S into a list and get an email when it puts out news.
Home listing price · OMXCOP:COLO_B
495.40 DKK -6.80 (-1.4%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, OMXCOP:COLO_B
- Day range
- 495.40 – 507.00 DKKNov 20, 2026
- Volume
- 362,032 sharesNov 20, 2026
- Market cap
- 102.7B DKKAt the close on Nov 20, 2026 · price × 207.4M shares outstanding
- 52-week range
- 369.70 – 590.40 DKKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 175.9M DKKMedian day 322,031 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Xetra:CBHD | €65.86 EUR | -0.66 (-1.0%) | 477 | €67.36 | €67.56 | €65.64 | €66.52 | Close on Nov 20, 2026 |
| OTC:CLPBY | $7.19 USD | -0.09 (-1.2%) | 11,981 | $7.31 | $7.35 | $7.19 | $7.28 | Close on Nov 20, 2026 |
| OTC:CLPBF | $74.45 USD | -0.87 (-1.2%) | 32 | $74.45 | $74.45 | $74.45 | $75.32 | Close on Nov 20, 2026 |
| Frankfurt:CBHD | €66.30 EUR | -0.34 (-0.5%) | — | €66.00 | €66.40 | €66.00 | €66.64 | Close on Nov 20, 2026 |
| Stuttgart:CBHD | €66.08 EUR | 0.00 (0.0%) | 82 | €66.02 | €67.78 | €66.02 | €66.08 | Close on Nov 20, 2026 |
| Frankfurt:CBH | €6.45 EUR | -0.15 (-2.3%) | — | €6.45 | €6.45 | €6.45 | €6.60 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXCOP:COLO_B · DKK, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 495.40 | -6.80 | -1.4% | 503.00 | 507.00 | 495.40 | 362,032 | |
| 502.20 | -5.80 | -1.1% | 505.20 | 512.60 | 502.20 | 250,827 | |
| 508.00 | -2.20 | -0.4% | 511.00 | 512.20 | 501.60 | 459,083 | |
| 510.20 | +2.20 | +0.4% | 509.40 | 512.20 | 507.20 | 303,818 | |
| 508.00 | +13.90 | +2.8% | 496.50 | 508.00 | 494.10 | 297,506 | |
| 494.10 | +0.90 | +0.2% | 500.40 | 503.80 | 491.40 | 244,407 | |
| 493.20 | +4.10 | +0.8% | 490.00 | 494.80 | 485.20 | 228,104 | |
| 489.10 | -19.10 | -3.8% | 499.20 | 503.40 | 486.30 | 524,402 | |
| 508.20 | -17.20 | -3.3% | 512.40 | 516.00 | 498.90 | 882,480 | |
| 525.40 | +2.60 | +0.5% | 527.40 | 530.00 | 514.80 | 617,588 | |
| 522.80 | +27.10 | +5.5% | 489.10 | 522.80 | 485.70 | 831,310 | |
| 495.70 | +14.30 | +3.0% | 449.90 | 495.70 | 447.00 | 1,122,083 | |
| 481.40 | -0.90 | -0.2% | 478.10 | 486.80 | 475.40 | 366,034 | |
| 482.30 | +5.30 | +1.1% | 483.00 | 487.90 | 480.40 | 474,132 | |
| 477.00 | -1.50 | -0.3% | 479.50 | 483.80 | 473.20 | 322,031 | |
| 478.50 | +1.00 | +0.2% | 476.50 | 478.70 | 471.50 | 255,141 | |
| 477.50 | -2.90 | -0.6% | 475.50 | 477.50 | 470.40 | 324,110 | |
| 480.40 | -4.30 | -0.9% | 485.00 | 485.50 | 477.70 | 308,560 | |
| 484.70 | +5.60 | +1.2% | 478.00 | 484.70 | 475.60 | 245,499 | |
| 479.10 | +9.70 | +2.1% | 471.70 | 479.10 | 470.00 | 371,082 | |
| 469.40 | -6.60 | -1.4% | 473.40 | 475.40 | 468.90 | 288,585 | |
| 476.00 | +9.10 | +1.9% | 472.00 | 477.00 | 471.30 | 290,070 | |
| 466.90 | -5.30 | -1.1% | 467.70 | 472.70 | 465.00 | 212,046 | |
| 472.20 | +3.70 | +0.8% | 465.00 | 473.10 | 462.30 | 268,492 | |
| 468.50 | +13.20 | +2.9% | 462.00 | 468.50 | 455.90 | 377,924 | |
| 455.30 | -0.60 | -0.1% | 459.00 | 461.60 | 453.90 | 261,605 | |
| 455.90 | +9.60 | +2.2% | 451.00 | 461.20 | 450.20 | 441,637 | |
| 446.30 | +10.40 | +2.4% | 438.10 | 446.80 | 436.00 | 293,894 | |
| 435.90 | +11.40 | +2.7% | 428.00 | 439.40 | 428.00 | 311,870 | |
| 424.50 | -1.80 | -0.4% | 426.30 | 428.30 | 421.30 | 424,172 | |
| 426.30 | +7.50 | +1.8% | 416.00 | 427.00 | 412.50 | 649,516 | |
| 418.80 | +8.80 | +2.1% | 414.20 | 423.20 | 413.40 | 407,344 | |
| 410.00 | -2.50 | -0.6% | 410.90 | 413.30 | 404.10 | 558,081 | |
| 412.50 | -2.80 | -0.7% | 413.60 | 415.30 | 410.60 | 357,668 | |
| 415.30 | -2.60 | -0.6% | 417.00 | 421.10 | 407.60 | 304,634 | |
| 417.90 | -1.10 | -0.3% | 422.90 | 424.20 | 417.90 | 334,274 | |
| 419.00 | -1.80 | -0.4% | 418.10 | 423.30 | 414.80 | 279,690 | |
| 420.80 | +3.20 | +0.8% | 421.20 | 423.80 | 415.60 | 323,630 | |
| 417.60 | -3.00 | -0.7% | 422.80 | 424.00 | 411.90 | 362,766 | |
| 420.60 | +1.00 | +0.2% | 420.40 | 424.90 | 417.10 | 282,768 | |
| 419.60 | -0.90 | -0.2% | 421.00 | 422.10 | 415.40 | 254,150 | |
| 420.50 | 0.00 | 0.0% | 422.50 | 423.90 | 415.30 | 314,066 | |
| 420.50 | +2.10 | +0.5% | 418.40 | 420.60 | 413.80 | 261,146 | |
| 418.40 | -1.70 | -0.4% | 419.90 | 423.00 | 417.60 | 628,560 | |
| 420.10 | +0.70 | +0.2% | 421.90 | 422.60 | 415.30 | 282,431 | |
| 419.40 | -0.30 | -0.1% | 420.30 | 422.40 | 416.30 | 240,656 | |
| 419.70 | +0.50 | +0.1% | 419.40 | 422.60 | 416.00 | 197,505 | |
| 419.20 | +3.10 | +0.7% | 420.00 | 426.40 | 419.00 | 288,478 | |
| 416.10 | -16.70 | -3.9% | 433.10 | 433.10 | 416.10 | 388,614 | |
| 432.80 | +0.80 | +0.2% | 431.20 | 437.50 | 430.30 | 229,430 | |
| 432.00 | -14.70 | -3.3% | 435.00 | 437.40 | 427.80 | 433,170 | |
| 446.70 | -6.10 | -1.3% | 453.80 | 458.30 | 446.70 | 287,035 | |
| 452.80 | -1.90 | -0.4% | 454.00 | 454.70 | 445.20 | 204,629 | |
| 454.70 | -9.20 | -2.0% | 466.00 | 467.70 | 454.60 | 254,925 | |
| 463.90 | -15.20 | -3.2% | 477.60 | 479.10 | 463.90 | 357,684 | |
| 479.10 | +9.70 | +2.1% | 474.10 | 483.50 | 467.10 | 680,857 | |
| 469.40 | +10.60 | +2.3% | 456.80 | 475.50 | 456.80 | 781,113 | |
| 458.80 | -3.90 | -0.8% | 461.30 | 463.90 | 456.20 | 385,763 | |
| 462.70 | +3.70 | +0.8% | 459.00 | 467.80 | 459.00 | 328,664 | |
| 459.00 | +4.80 | +1.1% | 451.80 | 459.00 | 447.30 | 321,125 | |
| 454.20 | -9.30 | -2.0% | 461.00 | 461.00 | 453.50 | 324,618 | |
| 463.50 | +1.00 | +0.2% | 456.20 | 464.00 | 453.00 | 501,485 | |
| 462.50 | +23.90 | +5.4% | 440.00 | 462.50 | 438.40 | 560,982 | |
| 438.60 | +2.80 | +0.6% | 432.90 | 438.60 | 429.80 | 201,355 | |
| 435.80 | -8.00 | -1.8% | 444.80 | 444.80 | 433.00 | 256,698 |
Splits
6 splits since 1993 · OMXCOP:COLO_B · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 5-for-1 | Split | |
| 2-for-1 | Split | |
| 2-for-1 | Split | |
| 3-for-2 | Split | |
| 3-for-2 | Split | |
| 5-for-1 | Split |
- Ticker
- Tradegate:CBHD
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- Tradegate
- Currency
- EUR
What changed lately
Latest news release · Sep 24, 2026
Coloplast A/S - Financial Calendar 2026/27
Latest earnings call · Aug 18, 2026
Coloplast (Copenhagen:COLO B) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Aug 18, 2026
Q3 2026 Earnings Presentation
Earnings · 10 slides
Latest news
Coloplast A/S - Financial Calendar 2026/27
Sep 24, 2026
Closed 420.60 (+0.2%) on Sep 24, 2026
Coloplast A/S - Announcement no. 05/2026 - Interim Financial Report, H1 2025/26
May 12, 2026
Closed 407.10 (+1.6%) on May 12, 2026
Coloplast Receives Innovative Technology Contract from Vizient for Biatain® Silicone Fit
May 1, 2026
Closed 402.80 (+2.3%) on May 1, 2026
Coloplast A/S - Coloplast revises financial guidance for FY 2025/26 to reflect reduced growth outlook for Kerecis
Apr 23, 2026
Closed 413.10 (-1.7%) on Apr 24, 2026
Coloplast A/S - H1 2025/26 Earnings Release - Invitation for conference call on 12 May 2026 at 11: 00 CEST
Apr 22, 2026
Closed 420.30 (-0.7%) on Apr 23, 2026
Coloplast A/S - Allocation of Share Options
Mar 10, 2026
Closed 453.60 (+1.1%) on Mar 10, 2026
Coloplast appoints Gavin Wood as new CEO
Mar 4, 2026
Closed 461.70 (-0.5%) on Mar 5, 2026
Coloplast A/S - Updated Financial Calendar 2025-26
Feb 11, 2026
Closed 489.00 (-0.6%) on Feb 11, 2026
Coloplast A/S - Interim Financial Report, Q1 2025/26
Feb 6, 2026
Closed 493.50 (-8.2%) on Feb 6, 2026
Coloplast A/S - Q1 2025/26 Earnings Release - Invitation for conference call on 6 Feb 2026 at 11.00am CET
Jan 26, 2026
Closed 540.00 (-0.3%) on Jan 26, 2026
Coloplast A/S on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 12 in the last 12 months · 23 in all · newest Sep 24, 2026 · oldest 2025
- Calls
- 11 calls with a replay · 11 with a transcript · latest Aug 18, 2026
- Decks
- 209 decks · latest Aug 18, 2026
Where Coloplast A/S is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Copenhagen:COLOB · Home listing | Copenhagen | Denmark | DKK |
| Xetra:CBHD | Xetra | Germany | EUR |
| LSIN:0QBO | LSIN | United Kingdom | DKK |
| OTC:CLPBY | OTC | United States | USD |
| gettex:CBHD | gettex | Germany | EUR |
| VIE:COLO | Vienna | Austria | EUR |
| Tradegate:CBHD · This page | Tradegate | Germany | EUR |
| OTC:CLPBF | OTC | United States | USD |
| Aquis:COLOBC | Aquis | United Kingdom | DKK |
| Frankfurt:CBHD | Frankfurt | Germany | EUR |
| gettex:CBH | gettex | Germany | EUR |
| LS Exchange:A1KAGC | LS Exchange | Germany | EUR |
| Lang & Schwarz:A1KAGC | Lang & Schwarz | Germany | EUR |
| Stuttgart:CBHD | Stuttgart | Germany | EUR |
| BX Swiss:CBHD | BX Swiss | Switzerland | CHF |
| Turquoise:COLOBC | Turquoise | United Kingdom | DKK |
| Dusseldorf:CBHD | Dusseldorf | Germany | EUR |
| Aquis:COLOBC | Aquis | United Kingdom | DKK |
| BMV:0QBON | BMV | Mexico | MXN |
| Hanover:CBHD | Hanover | Germany | EUR |
| Hamburg:CBHD | Hamburg | Germany | EUR |
| Munich:CBH | Munich | Germany | EUR |
| Munich:CBHD | Munich | Germany | EUR |
| BIVA:0QBON | BIVA | Mexico | MXN |
| Dusseldorf:CBH | Dusseldorf | Germany | EUR |
| Frankfurt:CBH | Frankfurt | Germany | EUR |
Valuation
P/E 33.4× against a median of 40.4×: 5th lowest of 10 Medical devices & supplies companies shown. Statements: Year to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- 123.7B DKK
- P/E
- 33.4×
- EV/sales
- 4.3×
- EV/EBITDA
- 10.5×
- Price/book
- 7.2×
- Gross margin
- 66.5%
- Operating margin
- 25.4%
- Net margin
- 10.6%
- Debt to equity
- 1.5×
- Beta
- No index for this market yet
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Coloplast A/S Class B · OMXCOP:COLO_B | US$15.08B | US$18.16B | 33.4× | 4.3× | 10.5× | 7.2× | 10.6% | 1.5× | n/a |
| Sonova Holding AG · SIX:SOON | US$20.69B | US$21.87B | 40.4× | 5.1× | 19.6× | 6.7× | 11.9% | 0.7× | n/a |
| Straumann Holding AG · SIX:STMN | US$20.27B | US$20.39B | 47.8× | 6.6× | 24.6× | 7.5× | 13.7% | 0.2× | n/a |
| Zimmer Biomet Holdings, Inc. · NYSE:ZBH | US$19.13B | US$26.24B | 24.9× | 3.1× | 11.6× | 1.5× | 8.9% | 0.6× | 0.40 |
| Shanghai United Imaging Healthcare Co., Ltd. Class A · SSE:688271 | US$14.48B | US$13.77B | 54.1× | 5.9× | n/a | 4.4× | 11.5% | 0.1× | n/a |
| Solventum Corporation · NYSE:SOLV | US$14.36B | US$18.98B | 92.1× | 2.3× | 20.0× | 3.0× | 1.9% | 1.1× | 0.56 |
| Baxter International Inc. · NYSE:BAX | US$13.14B | US$12.00B | n/a | 1.0× | 16.2× | 2.0× | −6.2% | 0.1× | 0.97 |
| Penumbra, Inc. · NYSE:PEN | US$12.58B | US$11.90B | 80.1× | 7.6× | n/a | 7.9× | 10.1% | 0.0× | 0.18 |
| Smith & Nephew plc · LSE:SN. | US$12.54B | US$15.58B | 20.1× | 2.5× | 11.4× | 2.4× | 10.1% | 0.7× | n/a |
| The Cooper Companies, Inc. · NASDAQ:COO | US$11.20B | US$13.59B | 19.6× | 3.2× | 14.6× | 1.3× | 13.5% | 0.3× | 0.50 |
| Align Technology, Inc. · NASDAQ:ALGN | US$11.02B | US$9.88B | 22.4× | 2.4× | 11.5× | 2.6× | 11.8% | 0.0× | 1.26 |
| Median of the others | US$13.75B | US$14.68B | 40.4× | 3.1× | 15.4× | 2.8× | 10.8% | 0.3× | 0.53 |
Forecasts
Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 473.81 DKK · Analysts' mean
- EPS, year to Sep 2027
- 24.99 · 20 analysts
- Revenue, year to Sep 2027
- 31.21B · 19 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Gavin Wood | President & CEO of Coloplast |
| Anders Lonning-Skovgaard | Executive Vice President, CFO |
| Julie Sommer Müggler | Coordinator & PA, Investor Relations |
| Kristine Husted Munk | Senior Director, Investor Relations |
| Nicklas Overgaard | Senior Manager, Investor Relations |
| Simone Dyrby Helvind | Sr. Manager, Investor Relations |
| Allan Rasmussen | Executive Vice President, Global Operations |
| Amanda Rajkumar | Executive Vice President, Chief People Officer |
| Caroline Vagner Rosenstand | Executive Vice President, Chronic Care Commercial |
| Kevin Hardage | Executive Vice President, Interventional Urology |
| Rasmus Just | Executive Vice President, Chronic Care R&D |
| Thomas Barfod | Senior Controller and member of the Coloplast Board |
Board
| Director | Role |
|---|---|
| Jette Nygaard-Andersen | Interim Chair of the Board |
Events
- Next results
- Feb 9, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Coloplast (Copenhagen:COLO B) Q3 2026 Earnings Call | Tue, Aug 18, 2026 · 5:00 AM ET | Replay |
| Coloplast (Copenhagen:COLO B) Q2 2026 Earnings Call | Tue, May 12, 2026 · 5:00 AM ET | Replay |
| Coloplast (Copenhagen:COLO B) Q1 2026 Earnings Call | Fri, Feb 06, 2026 · 12:00 PM ET | Replay |
| Coloplast (Copenhagen:COLO B) Q4 2025 Earnings Call | Tue, Nov 04, 2025 · 7:00 AM ET | Replay |
| Coloplast (Copenhagen:COLO B) Q3 2025 Earnings Call | Tue, Aug 19, 2025 · 5:00 AM ET | Replay |
| Coloplast (Copenhagen:COLO B) Q2 2025 Earnings Call | Tue, May 06, 2025 · 5:00 AM ET | Replay |
| Coloplast (Copenhagen:COLO B) Q1 2025 Earnings Call | Tue, Feb 04, 2025 · 5:00 AM ET | Replay |
| Coloplast (Copenhagen:COLO B) Q4 2024 Earnings Call | Tue, Nov 05, 2024 · 5:00 AM ET | Replay |
| Coloplast (Copenhagen:COLO B) Q3 2024 Earnings Call | Tue, Aug 20, 2024 · 5:00 AM ET | Replay |
| Coloplast (Copenhagen:COLO B) Q2 2024 Earnings Call | Tue, May 07, 2024 · 3:00 AM ET | Replay |
All 11 calls
| Call | When | Status |
|---|---|---|
| Coloplast (Copenhagen:COLO B) Q1 2024 Earnings Call | Fri, Feb 09, 2024 · 5:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q4 2026 | Nov 3, 2026 · After close | +5.5% |
| Q3 2026 | Aug 18, 2026 · Before open | +3.0% |
| Q2 2026 | May 12, 2026 · Before open | +1.6% |
| Q1 2026 | Feb 6, 2026 · Before open | −8.2% |
| Q4 2025 | Nov 4, 2025 · Before open | +4.8% |
| Q3 2025 | Aug 19, 2025 · Before open | −1.2% |
| Q2 2025 | May 6, 2025 · Before open | −6.0% |
| Q1 2025 | Feb 4, 2025 · Before open | −2.4% |
| Q4 2024 | Nov 5, 2024 · Before open | −0.3% |
| Q3 2024 | Aug 20, 2024 · Before open | −5.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2024 | May 7, 2024 · Before open | −3.5% |
| Q1 2024 | Feb 9, 2024 · Before open | +9.7% |
| Q4 2023 | Nov 9, 2023 · Before open | −6.9% |
| Q3 2023 | Aug 17, 2023 · Before open | −2.6% |
| Q2 2023 | May 11, 2023 · Before open | −4.3% |
| Q1 2023 | Feb 3, 2023 · Before open | −1.7% |
| Q4 2022 | Nov 7, 2022 · Before open | −2.1% |
| Q3 2022 | Aug 17, 2022 · Before open | +7.3% |
| Q2 2022 | May 5, 2022 · Before open | −5.5% |
| Q1 2022 | Jan 25, 2022 · Before open | +0.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 10 slides | Aug 18, 2026 |
| 9M 2025/26 Earnings Presentation | Earnings | 99 slides | August 2026 |
| Non-Deal Roadshow (May 2026) | Roadshow | 98 slides | May 2026 |
| Q1 2025/26 Earnings Presentation | Earnings | 9 slides | Feb 6, 2026 |
| Q1 2025/26 Earnings Presentation | Earnings | 94 slides | February 2026 |
| Q1 2025/26 Earnings Presentation | Earnings | 95 slides | February 2026 |
| Q2 2025/26 Earnings Presentation | Earnings | 4 slides | 2026 |
| Shareholder Meeting (December 2025) | Shareholder meeting | 37 slides | December 2025 |
| FY 2024/25 Earnings Presentation | Earnings | 10 slides | Nov 4, 2025 |
| Non-Deal Roadshow (November 2025) | Roadshow | 97 slides | November 2025 |
Show 50 decks
This page holds 50 of 209 decks. Open Decks
Financials
Annual, in DKK
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28.9B | 27.9B | 27.0B | 24.5B | 22.6B | 19.4B | 18.5B | 17.9B | 16.4B | 15.5B |
| Cost of revenue | 9.70B | 8.93B | 8.76B | 8.17B | 7.05B | 6.11B | 5.93B | 5.79B | 5.38B | 4.96B |
| Gross profit | 19.2B | 18.9B | 18.3B | 16.3B | 15.5B | 13.3B | 12.6B | 12.2B | 11.1B | 10.6B |
| Research and development | 1.07B | 946.0M | 913.0M | 872.0M | 866.0M | 755.0M | 708.0M | 692.0M | 640.0M | 574.0M |
| Selling, general and administrative | 10.8B | 1.24B | 1.11B | 1.00B | 762.0M | 762.0M | 757.0M | 653.0M | 623.0M | |
| Operating income | 7.36B | 7.20B | 7.32B | 6.77B | 6.44B | 6.36B | 5.85B | 5.16B | 5.09B | 5.02B |
| Depreciation and amortization | 4.43B | 863.0M | 839.0M | 1.07B | 930.0M | 792.0M | 851.0M | 651.0M | 625.0M | 611.0M |
| EBITDA | 11.8B | 8.06B | 8.16B | 7.84B | 7.37B | 7.15B | 6.71B | 5.81B | 5.72B | 5.63B |
| Interest expense | 747.0M | 1.15B | 1.10B | 719.0M | 240.0M | 57.0M | 63.0M | 54.0M | 44.0M | 45.0M |
| Income before tax | 3.85B | 6.16B | 6.39B | 6.03B | 6.13B | 6.23B | 5.47B | 5.03B | 5.01B | 4.95B |
| Income tax | 775.0M | 2.52B | 1.34B | 1.24B | 1.42B | 1.41B | 1.27B | 1.16B | 1.16B | 1.15B |
| Net income | 3.07B | 3.64B | 5.05B | 4.78B | 4.71B | 4.83B | 4.20B | 3.87B | 3.85B | 3.80B |
| Earnings per share, basic | 13.64 | 16.13 | 22.46 | 22.19 | 22.11 | 22.63 | 19.68 | 18.17 | 18.10 | 17.87 |
| Earnings per share, diluted | 16.13 | 22.46 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 511.0M | 947.0M | 788.0M | 911.0M | 414.0M | 448.0M | 323.0M | 356.0M | 297.0M | 314.0M |
| Short-term investments | -39.0M | 219.0M | 226.0M | 262.0M | 313.0M | 310.0M | 315.0M | |||
| Receivables | 5.00B | 4.66B | 4.67B | 4.59B | 4.32B | 3.44B | 3.27B | 3.35B | 3.07B | 3.15B |
| Inventory | 4.06B | 3.92B | 3.67B | 3.52B | 3.19B | 2.43B | 2.23B | 1.93B | 1.73B | 1.69B |
| Current assets | 9.95B | 10.5B | 10.4B | 9.94B | 8.77B | 6.99B | 6.49B | 6.36B | 5.59B | 6.19B |
| Property, plant and equipment | 6.20B | 5.65B | 4.13B | 3.58B | 3.16B | 2.84B | 2.90B | 2.69B | ||
| Goodwill | 16.5B | 19.3B | 19.4B | 20.0B | 11.8B | 2.03B | 1.98B | 2.03B | 1.98B | 1.72B |
| Total assets | 46.3B | 48.4B | 48.1B | 48.2B | 35.0B | 15.8B | 13.5B | 12.7B | 11.8B | 12.1B |
| Accounts payable | 1.70B | 1.32B | 1.52B | 1.29B | 1.24B | 1.04B | 814.0M | 859.0M | 751.0M | 675.0M |
| Current liabilities | 13.5B | 6.50B | 10.2B | 16.3B | 7.34B | 6.31B | 4.98B | 4.94B | 4.71B | 5.42B |
| Long-term debt | 13.6B | 19.4B | 16.6B | 11.6B | 16.4B | 0 | ||||
| Total debt | 21.5B | 22.6B | 22.6B | 19.6B | 18.7B | 2.79B | 1.75B | 1.21B | 1.36B | 1.46B |
| Total liabilities | 32.0B | 32.2B | 30.1B | 30.9B | 26.7B | 7.67B | 6.09B | 5.82B | 5.35B | 6.10B |
| Shareholders' equity | 14.3B | 16.1B | 17.9B | 17.3B | 8.29B | 8.17B | 7.41B | 6.91B | 6.42B | 5.95B |
| Shares outstanding | 225.4M | 225.4M | 224.9M | 215.5M | 212.8M | 213.2M | 213.3M | 213.1M | 212.4M | 212.5M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 8.01B | 6.64B | 2.77B | 4.23B | 5.10B | 5.29B | 4.76B | 4.36B | 4.36B | 3.25B |
| Capital spending | -1.39B | -1.31B | -1.17B | -1.24B | -1.14B | -1.97B | -931.0M | -636.0M | -669.0M | -685.0M |
| Free cash flow | 6.62B | 5.34B | 1.60B | 2.98B | 3.96B | 3.32B | 3.83B | 3.72B | 3.69B | 2.57B |
| Cash from investing | -1.73B | -1.25B | -1.34B | -8.96B | -11.8B | -2.01B | -901.0M | -591.0M | -947.0M | -1.62B |
| Cash from financing | -6.75B | -5.19B | -1.52B | 5.26B | 6.59B | -3.18B | -3.86B | -3.71B | -3.43B | -1.86B |
| Dividends paid | -5.18B | -4.96B | -4.72B | -4.25B | -4.04B | -3.83B | -3.61B | -3.40B | -3.29B | -2.86B |
| Share buybacks | 0 | -619.0M | -500.0M | -500.0M | -500.0M | -500.0M | -500.0M | |||
| Change in cash | -436.0M | 207.0M | -88.0M | 534.0M | -34.0M | 125.0M | -33.0M | 59.0M | -17.0M | -241.0M |
Cap table
Built by 6ix from Coloplast A/S Class B’s releases
- Common shares
- 207,368,138
- Fully diluted
- 207,368,138
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 207,368,138 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 207,368,138 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Allan Rasmussen | Executive Vice President, Global Operations · Since at least Jun 3, 2025 |
| Amanda Rajkumar | Executive Vice President, Chief People Officer · Since at least Nov 5, 2026 |
| Anders Lonning-Skovgaard | Executive Vice President, CFO · Since at least Sep 24, 2026 |
| Caroline Vagner Rosenstand | Executive Vice President, Chronic Care Commercial · Since at least Aug 19, 2025 |
| Gavin Wood | President & CEO of Coloplast · Since May 1, 2026 |
| Jette Nygaard-Andersen | Interim Chair of the Board · Since at least Mar 4, 2026 |
| Julie Sommer Müggler | Coordinator & PA, Investor Relations · Since at least Apr 22, 2026 |
| Kevin Hardage | Executive Vice President, Interventional Urology · Since at least Dec 18, 2025 |
| Kristine Husted Munk | Senior Director, Investor Relations · Since at least Sep 24, 2026 |
| Nicklas Overgaard | Senior Manager, Investor Relations · Since at least Sep 24, 2026 |
All 13 people
| Person | Seat |
|---|---|
| Rasmus Just | Executive Vice President, Chronic Care R&D · Since at least Aug 19, 2025 |
| Simone Dyrby Helvind | Sr. Manager, Investor Relations · Since at least May 12, 2026 |
| Thomas Barfod | Senior Controller and member of the Coloplast Board · Since at least Dec 4, 2025 |
Log in to ask 6ix AI your own questions about Coloplast A/S.